Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 44Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Mantle-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Smoldering Multiple Myeloma 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Immunoglobulin Light-chain Amyloidosis 3Brain Neoplasms 3Blast Crisis 3Plasmacytoma 2Neoplasms 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Hematologic Neoplasms 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Vomiting 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1POEMS Syndrome 1Ovarian Neoplasms 1

Interventions

Dexamethasone 38Melphalan 20Bortezomib 18Cyclophosphamide 17Calcium Dobesilate 14Filgrastim 13daratumumab 11Peripheral Blood Stem Cell Transplantation 10pomalidomide 9Lenalidomide 8fludarabine phosphate 7dexamethasone acetate 6Whole-Body Irradiation 6Mycophenolic Acid 6Granulocyte Colony-Stimulating Factor 5Cyclosporine 5venetoclax 4ixazomib 4dexamethasone 21-phosphate 4Thalidomide 4Etoposide 4Busulfan 4auricularum 3Tacrolimus 3Radiotherapy 3Focal Adhesion Protein-Tyrosine Kinases 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Immunoglobulin Light-chain Amyloidosis × auricularum × Clear all
NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡